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ABSTRACT
Purpose Currently, the FDA allows biowaivers for Class I
(high solubility and high permeability) and Class III (high sol-
ubi l i ty and low permeabi l i ty ) compounds of the
Biopharmaceutics Classification System (BCS). Scientific evi-
dence should be provided to support biowaivers for BCSClass
I and Class III (high solubility and low permeability)
compounds.
Methods Data on the effects of excipients on drug permeabil-
ity are needed to demonstrate that commonly used excipients
do not affect the permeability of BCS Class III compounds,
which would support the application of biowaivers to Class III
compounds. This study was designed to generate such data by
assessing the permeability of four BCS Class III compounds
and one Class I compound in the presence and absence of five
commonly used excipients.
Results The permeability of each of the compounds was
assessed, at three to five concentrations, with each excipient
in two different models: Caco-2 cell monolayers, and in situ rat
intestinal perfusion. No substantial increases in the permeabil-
ity of any of the compounds were observed in the presence of
any of the tested excipients in either of the models, with the
exception of disruption of Caco-2 cell monolayer integrity by
sodium lauryl sulfate at 0.1 mg/ml and higher.
Conclusion The results suggest that the absorption of these
four BCS Class III compounds would not be greatly affected
by the tested excipients. This may have implications in
supporting biowaivers for BCS Class III compounds in
general.
KEY WORDS BCS class III . bioavailability . Caco-2 .
permeability . rat intestinal perfusionmodel
ABBREVIATIONS
BA Bioavailability
BCS Biopharmaceutics classification system
BE Bioequivalence
IR Immediate-release







NEAA Non-essential amino acids




SEM Standard error of the mean
INTRODUCTION
The Biopharmaceutics Classification System (BCS) is a frame-
work for classifying drug substances based upon their aqueous
solubility and permeability across biological membranes (1).
The FDA BCS guidance (2) provides recommendations for
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sponsors of investigational new drug applications (INDs), new
drug applications (NDAs), abbreviated new drug applications
(ANDAs), and supplements to these applications (SNDA) who
wish to request a waiver of in vivo bioequivalence (BE) studies
for immediate-release (IR) solid oral dosage forms. Drug sub-
stances are classified based on their intestinal permeability (or
the fraction of oral dose absorbed) and aqueous solubility at
multiple pH values covering the range found in the gastroin-
testinal (GI) tract. The solubility class boundary is based ac-
cording to Papadopoulou et al. (3) the highest dose strength of
the drug substance in a pharmaceutical product that is dis-
solved in 250 ml (8 oz.) of aqueous buffer.
Class I drugs have high permeability, and high solubil-
ity at all pH values between 1.0 and 7.5 (original FDA
guidance from 2000), between 1.0 and 6.8 (new FDA
draft guidance, May 2015) (2) or between 1.2 and 6.8
(European Medicines Agency (EMA) and World Health
Organization (WHO) (4,5); such compounds are well
absorbed but may have poor bioavailability (BA) due to
extensive first-pass metabolism. Class II compounds have
high permeability, but their solubility is below the class
boundary at one or more pH values (e.g., at low pH for
acids or at neutral pH for bases). The fraction absorbed
may be limited by their solubility; therefore, it is not un-
common to see a wide range of extent of absorption for
this class of compounds. Class III drugs have low perme-
ability and high solubility, and their fraction absorbed is
sometimes limited by their permeability. Class IV drugs
have both low permeability and low solubility.
Class I drugs can be granted waivers from in vivo BE testing
(Bbiowaivers^) due to their consistently high fraction absorbed,
regardless of formulation (6). Several authors have suggested
that Class III compounds should also be eligible for biowaivers
if a new formulation does not change the permeability or the
GI transit time of the drug (7–9). WHO recommends, and the
new FDA draft guidance (2) makes provision for, biowaivers
for BCS Class III drug products, but only in cases where the
generic and comparator drug products are very rapidly dis-
solving and the excipients meet certain criteria (e.g., qualita-
tively the same, quantitatively very similar, well-established for
use in products containing that drug substance, do not affect
GI motility or interactions with transport processes, and do
not affect the pharmacokinetics (PK) of the drug substance)
(2,5). This suggestion has also been proposed based upon a
theoretical assessment of drug BA (10,11).
Certain excipients have been shown either to enhance the
in vitro permeability of drugs (e.g., by changing membrane
integrity or affecting transporters) or to modify GI transit time
(12,13). Limited human data also suggest that some excipients
may alter the BA of BCS Class III drugs (14,15). Several of
these excipients have been demonstrated to alter membrane
permeability directly, but others may work by inhibiting se-
cretory transport mechanisms (16).
In order to determine if a new formulation of a BCS III
drug is suitable for a biowaiver, the potential effect(s) of the
excipient(s) on permeability need to be evaluated. If no effect
can be discerned in a well-validated in vitromodel, it is reason-
able to expect no change in permeability in vivo as well (17–21).
First described for this purpose in 1989 (17), the utility of the
Caco-2 cell monolayer model for qualitative (e.g., rank-order
or high vs. low) prediction of the oral absorption of drugs has
been validated repeatedly since then (18–21).
This series of experiments had three objectives: 1) to deter-
mine whether a series of commonly used excipients would
alter the permeability of model drug compounds in both a
Caco-2 cell monolayer system (in vitro model) and an in situ
rat intestinal perfusion model (surrogate for human in vivo da-
ta); 2) to determine whether there was a correlation between
the Caco-2 and in situ rat intestinal perfusion models; and 3) to
evaluate the relative suitability of the two models for testing
the effects of excipients. The excipients were selected on the
basis of their aqueous solubility and prevalence in IR
formulations.
Five excipients were selected for testing: hydroxypropyl
methylcellulose (HPMC), povidone, polyethylene glycol
(PEG)-400, sodium lauryl sulfate (SLS), and lactose. All of
these are commonly used in oral formulations, and some have
been shown to act as penetration enhancers (16). The model
compounds evaluated for permeability were antipyrine (BCS
Class I), acyclovir (Class III), atenolol (Class III), ganciclovir
(Class III), and nadolol (Class III) (22). The Class III com-
pounds were selected because they are not substrates of P-gp
and because they represent a range of the in vivo fraction
absorbed, with atenolol > nadolol > acyclovir > ganciclovir




Ganciclovir was obtained from Toronto Research Chemicals
(Toronto, Ontario, Canada). Acyclovir, antipyrine, atenolol,
nadolol, digoxin, propranolol, D-glucose, D-lactose
monohydrate, povidone K15, HPMC, PEG-400, SLS, 2-(N-
morpholino)ethanesulfonic acid (MES), and Krebs Ringers
buffer (KRB) were obtained from Sigma-Aldrich (St. Louis,
MO, USA). Lucifer yellow (LY), Hanks’ balanced salt solution
(HBSS), Dulbecco’s modified Eagle’s medium (DMEM), and
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
were obtained from Invitrogen (Carlsbad, CA, USA). Fetal
bovine serum (FBS) was obtained from Omega (Tarzana,
CA, USA). Penicillin, streptomycin, non-essential amino acids
(NEAA), and trypsin-EDTA were obtained from CelGro
(Herndon, VA, USA). Costar® tissue culture flasks and dual-
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chamber Transwell® plates were obtained from Corning
(Corning, NY, USA).
The excipients used and their respective concentrations are
given in Table I. The selection of the excipients and the con-
centrations used in the study were based on information ob-
tained from the FDA’s Inactive Ingredient Database (24). The
inclusion criteria for selection of the excipient and the concen-
trations included the frequency at which the excipient is used
(they are all commonly used), the amount of excipient typical-
ly used, the solubility of the excipient in physiological fluids,
and the concentration of the excipient in the commonly used
dosing volume of 250 ml. This may be an important factor in
determining the choice of excipients in new formulations.
Bioanalysis
A liquid chromatography–tandem mass spectroscopy (LC-
MS/MS) analytical method was developed and validated for
the simultaneous determination of the five compounds (acy-
clovir, antipyrine, atenolol, ganciclovir, and nadolol) in the
presence of five excipients (HPMC, povidone, PEG-400,
SLS, and lactose). The analytical system was a PE SCIEX
API 3000 LC-MS/MS with Flux Instruments Rheos 2000
pumps, a CTC Analytics autosampler, and an on-line
degassing system. The LC column was a Thermo Aquasil
C18 (3 μm, 50×2.1 mm) run at 300 μl/min with a 9-min
gradient from 90% water/10% ammonium formate buffer
(40 mM, pH 3.5) to 90% acetonitrile/10% ammonium for-
mate buffer. Accuracy, based on analysis of replicate stan-
dards at 1 μM, was between 98.8 and 107% for all analytes,
with coefficients of variation ranging from 2.6 to 5.9%. Sim-
i lar accuracy and precis ion were found at lower
concentrations.
Caco-2 Cells
Caco-2 cells (clone C2BBe1) were cultured in DMEM supple-
mented with 10% FBS, 1 mM sodium pyruvate, 100 μM
NEAA, 2 mM L-glutamine, 100 U/ml penicillin, and
100 μg/ml streptomycin. Stock cultures were grown in 175-
cm2 flasks at 37°C in a humidified atmosphere containing 5%
CO2. Cells were harvested with trypsin-EDTA, seeded at a
density of 60,000 cells/cm2 on collagen-coated Transwell
plates (0.4-μm pore size), and grown at 37°C in a humidified
atmosphere containing 5% CO2. The culture medium was
changed every other day for 10 days, and daily thereafter. Cell
monolayers on Transwell plates were used for transport assays
between 21 and 28 days post- seeding. Prior to use, each batch
of monolayers was certified by measuring the transepithelial
electrical resistance and the permeability of atenolol, propran-
olol, LY, and digoxin.
Permeability Across Caco-2 Cell Monolayers
Non-specific Binding and Recovery Assessment
Acyclovir (100 μM), antipyrine (10 μM), atenolol
(100 μM), ganciclovir (100 μM), and nadolol (100 μM)
were dosed together as a cassette in the apical chamber
of a cell-free Transwell device (n=3 replicates) to deter-
mine the non-specific binding (recovery) and cell-free ap-
parent permeability across the membrane of each com-
pound. Samples were collected from the donor and re-
ceiver chambers at multiple time points and analyzed by
LC-MS/MS. BCassette^ refers to a small set of drugs (e.g.,
3–5) or other compounds that are dosed together (co-
dosed) for evaluation of their permeability (in vitro), ab-
sorption (in situ), or BA (in vivo). The assumption is that
they do not interact with each other or interfere with each
other’s absorption, in which case the co-dosed results
should reflect the results that would be obtained if they
were dosed individually.
Permeability Assay
The unidirectional (apical-to-basolateral (A→B)) and bidirec-
tional (A→B and B→A) permeability of acyclovir, antipyrine,
atenolol, ganciclovir, and nadolol, dosed as a cassette, was
determined with Caco-2 cell monolayers. Bidirectional per-
meability was measured in the absence of excipients only (n=3
replicates), whereas unidirectional permeability was measured
both in the presence and absence of excipients (n=4 repli-
cates). The transport buffer was HBSS, supplemented with
10 mM MES or HEPES buffer and 10 mM D-glucose
(15 mM D-glucose final concentration). The pH of the buffer
in the apical (A→B donor, B→A receiver) chamber was 6.8,
and the pH of the buffer in the basolateral (A→B receiver,
B→A donor) chamber was 7.4. The apparent permeability (Papp)
and recovery were calculated as follows:
Papp ¼ dCr=dtð ÞV r= A C0ð Þ
Percent Recovery ¼ 100
 V r  C rfinalð Þ þ V d  Cd finalð Þ½ = V d  C0ð Þ
Efflux ratio ¼ Papp B→Að Þ= Papp A→Bð Þ
dCr/dt is the rate of appearance of the compound in the re-
ceiver compartment (μM/sec); Vr and Vd are the volumes of
the receiver and donor compartments, respectively (cm3); A is
the surface area of the cell monolayer (1.13 cm2); C0 is the
concentration (μM) of the dosing solution; and Cr final and Cd
final are the concentrations (μM) in the receiver and donor
compartments, respectively, at the end of the incubation
period.
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Permeability Across Rat Jejunum in Recirculating
Intestinal Perfusion Model
Test System
Sprague–Dawley rats (300–350 g) were used to perform
closed-loop, in situ intestinal perfusion. Rats were fasted for
12–18 h before the experiment, and water was supplied ad
libitum.
Study Design
Four rats (n=4) were used per treatment group, with a total of
17 groups: one control group (assay buffer, no excipients) and
three or four treatment groups for each of the five excipients,
with a different concentration for each group. The
recirculating intestinal perfusion was performed with the five
compounds dosed as a cassette (100 μM acyclovir, 10 μM
antipyrine, 100 μM atenolol, 100 μM ganciclovir, and
100 μM nadolol) in KRB with 10 mM MES, pH 6.8.
Test Method
Rats were anesthetized with an intraperitoneal injection of
ketamine/xylazine (1 ml/kg) and placed on a heating pad to
maintain normal body temperature. After making a midline
incision, the intestines were externalized. A 10-cm segment of
the jejunum was tied off, cannulated at both ends to form a
loop, and flushed with saline and air. The loop was equilibrat-
ed statically with dosing solution for 30 min, then flushed with
air and perfused by recirculation (peristaltic pump) with 10 ml
dosing solution at 0.2 ml/min. Samples of the perfusate were
taken from the reservoir at 15, 30, 45, 60, 75, and 90 min for
analysis by LC-MS/MS.
Sample and Data Analysis
The effective permeability coefficient, Peff (cm/s), was calcu-
lated as
Peff ¼ ‐ d ln C=C0½ ð Þ=dtð Þ  V =2πrl
where C is the concentration at a given time and C0 is the
concentration in the dosing solution (μM); d(ln C/C0)/dt is
the slope of a plot of the natural log of the concentration ratio
in the perfusate vs. time (sec−1) at steady state, corrected for the
apparent loss (due to dilution) of the impermeant marker FD-
4 (fluorescein-conjugated dextran with a molecular weight of
4 kDa); V is the volume of the dosing solution (10 cm3); 2πrl is
the luminal surface area (cm2), based on a radius (r) of
0.178 cm for the rat intestine (25) and the measured length
of each intestinal segment, l (cm).
RESULTS
LC-MS/MS
The LC-MS/MS method for acyclovir, antipyrine, atenolol,
ganciclovir, and nadolol cassette analysis—in the presence
and absence of the excipients HPMC, povidone, PEG-400,
SLS, and lactose—had adequate sensitivity and selectivity and
was valid for use in this study. The lower limit of quantification
(LLOQ) was 0.005 μM, and the upper limit of quantification
(ULOQ) was 1 μM for all analytes. The intra- and inter-assay
accuracy and precision were within ±12% of nominal at all
concentration levels in all three matrices (HBSSg, pH 7.4;
HBSSg, pH 6.8; and KRB, pH 6.8). Benchtop, autosampler,
and refrigerator stability were adequate, and no significant
endogenous interference was found from HPMC, povidone,
SLS, PEG-400, or lactose.
Table II Non-specific Binding and Recovery of Antipyrine, Acyclovir, Aten-
olol, Ganciclovir and Nadolol from Cell-Free Permeability Test Devices
Compound (μM) Cell-free Papp (10
−6 cm/s)a Recovery (%)
Acyclovir (100) 29.8±1.8 86.1±1.7
Antipyrine (10) 34.8±0.8 85.8±2.1
Atenolol (100) 33.8±0.7 102±1.1
Ganciclovir (100) 31.1±1.4 92.3±1.6
Nadolol (100) 33.0±0.7 101±1.5
Data presented as mean±SD, n=3
a For example, a value of B1.0^ represents a Papp of 1.0×10
−6 cm/s
Table I Concentrations of Excipients Tested in the Two Permeability Models
Excipient Concentrations In Caco-2 (mg/ml) Concentrations in rat intestinal perfusion (mg/ml)
Lactose 0.024, 0.13, 0.24, 1.0, 2.0 0.024, 0.13, 0.24
HPMC 0.012, 0.036, 0.06, 1.0, 2.0 0.012, 0.036, 0.06
PEG-400 0.015, 0.06, 0.18, 0.30 0.06, 0.18, 0.30
Povidone 0.024, 0.042, 0.06, 0.1, 0.2 0.024, 0.042, 0.06
SLS 0.01, 0.02, 0.04, 0.10, 0.17 0.01, 0.02, 0.04, 0.17
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Table IV Effects of Excipients on
In Vitro Caco-2 Cell Monolayer
Permeability
Excipient Conc., mg/ml Apparent permeability coefficient (Papp) (10
−6 cm/s)
Antipyrine Acyclovir Atenolol Ganciclovir Nadolol
Controla 39.9±2.14 0.28±0.06 0.23±0.05 0.25±0.06 0.21±0.06
Controlb 43.6±0.89 0.28±0.06 0.25±0.05 0.22±0.05 0.21±0.04
D-Lactose 0.024a 42.3±5.53 0.18±0.04 0.19±0.05 0.14±0.04 0.14±0.04
0.13a 41.6±0.58 0.32±0.11 0.57±0.46 0.48±0.42 0.44±0.37
0.24a 39.8±0.55 0.31±0.20 0.27±0.19 0.28±0.19 0.27±0.20
1.0b 33.3±0.85 0.20±0.05 0.16±0.06 0.17±0.05 0.14±0.05
2.0b 33.1±1.32 0.17±0.14 0.14±0.01 0.16±0.01 0.13±0.01
Povidone 0.024a 44.5±0.91 0.17±0.02 0.14±0.01 0.15±0.01 0.11±0.01
0.042a 40.4±0.96 0.21±0.03 0.15±0.02 0.18±0.03 0.13±0.02
0.06a 41.9±0.30 0.14±0.004 0.11±0.003 0.12±0.002 0.09±0.02
0.1b 38.5±1.56 0.19±0.05 0.13±0.03 0.16±0.04 0.12±0.03
0.2b 36.3±0.56 0.23±0.06 0.16±0.05 0.19±0.05 0.15±0.05
HPMC 0.012a 40.8±0.99 0.15±0.01 0.12±0.01 0.14±0.01 0.11±0.01
0.036a 37.3±1.33 0.18±0.04 0.14±0.04 0.15±0.04 0.14±0.03
0.06a 39.2±1.63 0.17±0.05 0.14±0.05 0.15±0.05 0.14±0.05
1.0b 33.2±1.51 0.20±0.06 0.15±0.05 0.16±0.05 0.13±0.05
2.0b 33.5±0.29 0.17±0.03 0.13±0.02 0.15±0.03 0.11±0.02
SLS 0.01a 46.9±2.50 0.25±0.07 0.24±0.07 0.21±0.07 0.23±0.07
0.02a 40.9±1.11 0.34±0.04 0.32±0.05 0.30±0.04 0.31±0.05
0.04a 45.9±0.56 0.35±0.11 0.39±0.12 0.30±0.10 0.31±0.10
0.1a,c 36.6±1.23 2.48±1.08 2.14±0.96 2.23±0.98 1.98±0.87
0.17 Not determined due to disruption of monolayer integrity
PEG 400 0.015b 40.7±0.96 0.34±0.04 0.29±0.04 0.30±0.04 0.27±0.04
0.06a 38.9±0.49 0.17±0.01 0.17±0.01 0.16±0.01 0.13±0.01
0.18a 37.2±0.53 0.22±0.06 0.18±0.05 0.20±0.05 0.14±0.04
0.30a 37.2±0.68 0.19±0.06 0.16±0.05 0.18±0.05 0.12±0.04
Data presented as mean±SEM (n=4)
a,b Two separate sets of controls were run, each in parallel with a batch of test wells with excipients
c Integrity of Caco-2 cell monolayers was compromised (LY Papp 0.18×10
−6 cm/s with buffer only; 0.30×10−6 cm/s
with test compounds only (no excipients); 0.05×10−6 cm/s with 0.01mg/ml SLS; 0.16×10−6 cm/s with 0.02mg/ml
SLS; 0.20×10−6 cm/s with 0.04 mg/ml SLS; 2.20×10−6 cm/s with 0.1 mg/ml SLS; 4.61×10−6 cm/s with
0.17 mg/ml SLS)
Table III Bidirectional Permeability and Recovery of Antipyrine, Acyclovir, Atenolol, Ganciclovir and Nadolol Across Caco-2 Cell Monolayers
Compound (μM) A→B B→A Efflux ratiob
Papp (10
−6 cm/s)a Recovery (%) Papp (10
−6 cm/s)a Recovery (%)
Acyclovir (100) 0.32±0.14 82.2±8.6 0.85±0.11 94.9±12.2 2.7
Antipyrine (10) 44.5±0.70 104±3.1 52.5±3.80 98.8±9.60 1.2
Atenolol (100) 0.29±0.14 83.6±9.2 0.62±0.08 94.0±11.0 2.2
Ganciclovir (100) 0.32±0.16 82.9±7.3 0.70±0.09 92.7±10.8 2.1
Nadolol (100) 0.29±0.16 83.9±9.1 0.71±0.15 90.7±12.2 2.5
Data presented as mean±SD, n=3
a For example, a value of B1.0^ represents a Papp of 1.0×10
−6 cm/s
b Efflux ratio is calculated from the mean Papp value in each direction
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Bidirectional Permeability
As shown in Table II, all five compounds in the cassette had
recoveries of at least 85% and high cell-free permeability un-
der A→B test conditions. High recovery indicates little loss to
either non-specific binding to the device or chemical instabil-
ity during the assay, and high cell-free Pappindicates that the
compounds were freely diffusible across the membrane (lack
of aggregation, etc.).
The bidirectional permeability results presented in
Table III demonstrate that the BCS Class I compound anti-
pyrine had much higher permeability across Caco-2 cell
monolayers than the other four model compounds in the cas-
sette (all of which were BCS Class III compounds), with
complete recovery and no significant efflux (efflux ratio was
approximately equal to 1). The permeability of acyclovir,
atenolol, ganciclovir, and nadolol were each quite low and
similar in magnitude to each other; the efflux ratios ranged
from 2.1 to 2.7.
Unidirectional Permeability
The concentrations of the excipients tested are shown in
Table I. The concentrations (in mg/ml) are shown with the
two permeability models, Caco-2 cells and rat intestinal
perfusion.
The results presented in Table IV demonstrate no consis-

























Fig. 1 Papp vs. D-Lactose
concentration.
Table V Effects of Excipients on In Situ Rat Jejunal Permeability
Excipient Conc., mg/ml Effective permeability coefficient (Peff) (10
−4 cm/s)
Antipyrine Acyclovir Atenolol Ganciclovir Nadolol
Control 1.43±0.17 −0.42±0.24 −0.33±0.22 −0.24±0.17 −0.41±0.19
D-Lactose 0.024 1.40±0.20 −0.51±0.09 −0.53±0.09 −0.44±0.09 −0.44±0.08
0.13 1.28±0.06 −0.09±0.36 −0.17±0.36 −0.10±0.19 −0.21±0.17
0.24 2.03±0.38 −0.26±0.22 −0.16±0.28 −0.11±0.17 −0.17±0.24
Povidone 0.024 1.63±0.34 0.16±0.19 0.21±0.17 0.05±0.15 0.13±0.015
0.042 1.15±0.07 −0.22±0.24 −0.20±0.21 −0.10±0.18 −0.11±0.16
0.06 1.33±0.42 0.03±0.14 0.12±0.15 −0.25±0.09 −0.23±0.08
HPMC 0.012 1.43±0.21 0.35±0.18 0.36±0.19 0.10±0.17 0.07±0.17
0.036 0.91±0.19 0.05±0.06 0.00±0.07 −0.04±0.03 −0.12±0.03
0.06 1.68±0.35 0.21±0.14 0.06±0.03 0.27±0.07 0.40±0.07
SLS 0.01 1.75±0.23 0.19±0.012 0.46±0.13 0.23±0.15 0.32±0.15
0.02 0.93±0.26 0.41±0.07 0.46±0.09 0.36±0.07 0.37±0.10
0.04 1.08±0.18 −0.05±0.07 0.02±0.05 0.00±0.01 0.01±0.02
0.17 1.57±0.46 −0.38±0.14 −0.30±0.17 −0.28±0.14 −0.36±0.10
PEG 400 0.06 1.17±0.22 0.17±0.07 0.29±0.07 0.26±0.07 0.24±0.08
0.18 0.90±0.26 0.27±0.14 0.27±0.13 0.30±0.09 0.25±0.08
0.30 0.82±0.15 0.07±0.02 0.09±0.03 0.02±0.05 0.01±0.01
0.30a 1.53±0.18 −0.21±0.19 −0.13±0.20 −0.24±0.13 −0.23±0.13
Data presented as mean±SEM (n=4)
a Second run
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the model compounds across Caco-2 cell monolayers in the
A→B (physiological absorptive) direction in the presence of
up to 2.0 mg/ml lactose, 0.2 mg/ml povidone, 2.0 mg/ml
HPMC, 0.04 mg/ml SLS, or 0.3 mg/ml PEG-400. The same
was true for monolayer integrity (data not shown). On the
other hand, SLS at concentrations of 0.1 and 0.17 mg/ml
increased the post-experiment permeability of the monolayer
integrity marker LY, indicative of damage to the cell mono-
layer (see footnote to Table IV). The permeability of the mod-
el compounds in the presence of 0.1 mg/ml SLS was approx-
imately 10-fold higher than control; permeability in the pres-
ence of 0.17 mg/ml SLS was not determined due to the evi-
dent cell monolayer damage.
Permeability in the Recirculating In Situ Rat Intestinal
Perfusion Model
As shown in Table V and in Figs. 1, 2, 3, 4, and 5, the per-
meability results in the recirculating in situ rat intestinal perfu-
sion model also suggest that lactose (up to 0.24 mg/ml),
povidone (up to 0.06 mg/ml), HPMC (up to 0.06 mg/ml),
SLS (up to 0.17 mg/ml), and of PEG-400 (up to 0.3 mg/ml)
do not have a substantial effect on the permeability of the
model compounds across rat jejunum. The small sample size
precludes definitive conclusions regarding statistical
significance.
The permeability data were noticeably less variable in the
Caco-2 model than in the in situ rat perfusion model: median
relative standard deviation for antipyrine of 2.64% in the
Caco-2 model vs. 18.5% in the rat perfusion model; a range
of 17.0 to 19.4% for the Class III compounds in the Caco-2
model vs. 46.4 to 65.2% in the rat perfusion model.
DISCUSSION
An LC-MS/MS method was validated for acyclovir, antipy-
rine, atenolol, ganciclovir, and nadolol determinations as a
cassette in the absence and presence of excipients. This ap-
proach allowed for a relatively rapid assessment of the results
of both arms of the study. This approach may be used to test
the effects of other excipients on the same model compounds.
The permeability of all five model compounds across intes-
tinal epithelia was measured both in vitro (Caco-2 cell
monolayers) and in situ (rat intestinal perfusion). One problem
with the intestinal perfusion model is that negative Peff values
are often observed for low-permeability compounds. The
most likely reason for a negative Peff value is that net water
flux cannot be assessed accurately. When a small amount of a
supposedly Bimpermeable^ marker (FD-4 in this case, used to
correct for water secretion) is absorbed, mathematically it re-
sults in overcorrection for water secretion, resulting in nega-
tive Peff values for low-permeability compounds. Currently,
there are no perfect markers for the rat intestinal perfusion
model. FD-4 was used as the impermeable marker in this
study, since this marker is widely accepted in the literature.
Although negative Peff values for low-permeability com-
pounds suggest that the rat perfusion model may be variable


















































Fig. 2 Papp vs. Povidone
concentration.
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absorption, this system is widely accepted for the evaluation of
permeability.
The permeability of the BCS Class I compound antipyrine
across Caco-2 cell monolayers was high in both directions,
with no asymmetry (ratio of B→A Papp to A→B Papp near
unity). The Caco-2 A→B (absorptive direction) permeability
of the Class III model compounds acyclovir, atenolol, ganci-
clovir, and nadolol were all very low and nearly identical in
magnitude (between 0.29×10−6 and 0.32×10−6 cm/s). The
efflux ratios of the Class III compounds ranged from 2.1 to
2.7, a moderate degree of apparent efflux that is due in part to
the fact that, in each case, the recovery was somewhat lower in
the A→B direction than in the B→A direction, which would
tend to underestimate the Papp in the A→B direction (the
denominator in the efflux ratio), leading to an overestimate
of efflux. Clinically, linear peak plasma concentration as a
function of oral dose (PK) has been reported for atenolol
(26) and nadolol (27), suggesting no significant interaction with
efflux transporters. For acyclovir (28) and ganciclovir (29),
decreasing exposure as a function of dose has been reported
after oral administration; this is evidence for possible involve-
ment of active intestinal uptake and is not consistent with an
interaction with efflux transporters.
With the exception of an effect of SLS on Caco-2 cell
monolayers at concentrations of 0.1 and 0.17 mg/ml, where
cell monolayer integrity was clearly compromised, none of the
tested excipients caused a substantial increase in the perme-
ability of any of the model compounds in either model. The
effect of SLS on Caco-2 cell monolayer integrity at higher test
concentrations was clearly a model-specific toxic effect, and
therefore may not be pharmaceutically relevant. Other studies
have reported positive effects of excipients on the permeability
of different drugs, but the effects appear to be dependent on
the excipient and its concentration (12,30–32). For example,
sorbitol and SLS reduce the bioavailability of the Class I drug
risperidone, the former due to increased GI motility and the
latter by an unknown mechanism (33). With the exception of
SLS at the two highest tested concentrations, the excipients
used in this study do not appear to disrupt cell monolayer
integrity at the concentrations used, whereas some of the ex-
cipients used in other studies (e.g., sodium caprate (31)) may
be more likely to do so.
This study focused on the effects of individual excipients on
permeability and did not evaluate the effects of combining
multiple excipients (which would be commonly done in an
IR formulation) on permeability. Because of the vast number
of excipient combinations and concentration combinations,
testing for the synergistic effects of combinations was not
feasible.
While the limitations of the Caco-2 cell monolayer model
(like any other preclinical model) are appreciated by inves-
tigators in the field, the FDA does accept Caco-2 data for
BCS classification. In spite of its limitations, based on the
fact that Caco-2 permeability data have lower variability
between replicates than data obtained from in situ
recirculating rat intestinal perfusion, the Caco-2 cell mono-
layer model may be more sensitive in terms of detecting
effects of an excipient on drug permeability. On the other
hand, Caco-2 cell monolayers may be overly sensitive to
some excipients, as with SLS at or above 0.1 mg/ml. There-
fore, a positive result may need to be followed up in vivo to



















































Fig. 4 Papp vs. SLS concentration.
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Except for SLS at concentrations at or above 0.1 mg/ml (at
which concentrations the effects are on monolayer integrity
rather than due to permeability enhancement), the results of
this study with a set of four BCS Class III model compounds
support the more general hypothesis that these five commonly
used excipients do not affect the permeability of BCS Class III
compounds. Biowaivers for Class III compounds should be
considered when excipients used in a formulation have been
shown not to affect permeability. There are many recent ex-
amples of biowaivers granted by the WHO for Class III drugs
(34–38), as well as the assessment that BE of many of the IR
drug products available today can be assured with an in vitro
dissolution test (39). The results of this study support
biowaivers for BCS Class III compounds. This would reduce
the amount of time needed to get new formulations to patients
who need them, reduce the cost of developing new formula-
tions, and reduce the cost of modifying or improving the
manufacturing process for products containing Class III
drugs. From an ethical point of view, it also reduces the need-
less exposure of healthy volunteers to drugs without therapeu-
tic benefit.
CONCLUSION
The influence of five excipients (lactose, povidone, HPMC,
SLS, and PEG400), commonly used in IR formulations, on
the permeability of five model drugs (acyclovir, antipyrine,
atenolol, ganciclovir, and nadolol) was investigated. Two test
systems were used: Caco-2 cell monolayers and in situ
recirculating rat intestinal perfusion; both have been used
for absorption enhancement studies. Within the tested con-
centration range for all drug–excipient combinations, the ex-
cipients caused no substantial increases in drug permeability,
except in the case of SLS at concentrations (0.1 mg/ml and
higher) where cell monolayer integrity was compromised.
These results should support biowaivers for BCS Class III
(high solubility–low permeability) compounds, but only for
compounds similar in permeability to those tested and which
have been formulated with the excipients used in this study.
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